NEW PROVIDENCE, N.J.--(BUSINESS WIRE)--Edge Therapeutics announced today the election of Robert Spiegel, M.D., FACP, to the Company's Board of Directors.
Dr. Spiegel spent over 25 years at Schering-Plough where he was deeply involved in clinical development culminating with his position as Chief Medical Officer. Dr. Spiegel retired in 2009 as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. While at Schering-Plough, Dr. Spiegel was involved in the filing of over 30 New Drug Applications and interacted with regulatory authorities in the U.S. and globally on a regular basis, serving on the executive committees overseeing all research projects and drug licensing activities. Dr. Spiegel joined Schering-Plough in 1983 as Director, Clinical Research, progressing through clinical operations as Vice President of Clinical Research, Senior Vice President of Worldwide Clinical Research and then becoming Chief Medical Officer in 1998. He received his undergraduate degree, cum laude, from Yale University and his medical degree from the University of Pennsylvania. Dr. Spiegel has served on the Boards of Directors of a number of companies including: Geron Corporation, Talon Therapeutics, Capstone Therapeutics, and Clavis Pharma ASA. He is an Associate Professor at Weill Cornell Medical College and serves on the Board of Directors of Cancer Care, Inc. Additionally, he is an Advisor at Warburg Pincus.
"We are honored that Bob is joining our board and sharing his wealth of clinical development experience and his knowledge of regulatory authorities worldwide," said Brian Leuthner, President and CEO of Edge. "He will prove to be a tremendous asset as the Company advances its strategy to become a successful international hospital-focused drug company."
Dr. Sol Barer, Edge Therapeutics Board Chairman noted: "With the addition of Bob to the Board, we acquire significant clinical and regulatory expertise from a person who shares common values that focus on the patient and the development of therapies for life threatening diseases."
"Edge presents an exciting opportunity to develop potential breakthrough therapies for treating brain hemorrhages and other debilitating critical care conditions," said Dr. Spiegel. "I look forward to working with the Company's board and management team during this exciting time of growth for Edge Therapeutics and to help bring new treatment options to these critical patient populations."
About Edge Therapeutics
Edge Therapeutics, Inc. is a private, clinical-stage biopharmaceutical company focused on developing and commercializing life-saving hospital products that improve patient outcome by addressing acute, fatal or debilitating conditions after brain hemorrhage that have no current effective treatment. Edge uses its novel site-specific and sustained-release microparticle technology platform to deliver drugs to the brain to prevent complications of subarachnoid hemorrhage, subdural hematoma and intracerebral hemorrhage, all of which currently have no effective therapies. The Company's patent-protected bio-absorbable microparticle formulations release drugs locally and consistently at therapeutic concentrations in the brain, with the objective of maximizing therapeutic activity and avoiding treatment-limiting systemic side effects seen with current treatments. Currently, oral- or IV-administered therapies are employed in suboptimal concentrations due to the generation of systemic side effects. Edge's lead product candidates, EG-1962 (nimodipine microparticles) and EG-1964, are being developed to prevent various delayed complications after brain hemorrhage. EG-1962 is a proprietary microparticle formulation of the calcium channel blocker nimodipine, while EG-1964 delivers a hemostatic agent. For more information on Edge Therapeutics, Inc., please visit: www.edgetherapeutics.com.
Edge Therapeutics, Inc.
Brian A. Leuthner, 800-208-EDGE
President & CEO